What are the new blockbuster medicines to watch? In this podcast we feature an article that examines the eleven medicines projected to enter the market in 2020 and achieve blockbuster status by 2024, according to a recent analysis by Clarivate Analytics’ Cortellis Forecast Team. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Blockbuster watch: Big Pharma
- Novo Nordisk’s Rybelsus (semaglutide)
- AstraZeneca’s and Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki)
- Immunomedics’ sacituzumab govitecan
- Bristol-Myers Squibb’s liso-cel (or lisocabtagene maraleucel),
- Bristol-Myers Squibb’s ozanimod
- Novartis’ ofatumumab (subcutaneous)
- Novartis’ inclisiran
- Gilead Sciences’ filgotinib
- Akebia Therapeutics’, Mitsubishi Tanabe Pharma’s, and Otsuka Pharmaceutical’s vadadustat
- BioMarin Pharmaceutical’s Valrox
- Biohaven Pharmaceuticals’ rimegepant
Sponsor: CordenPharma
